Northwestern University Feinberg School of Medicine

Department of Medicine

Clinical Trials

As part of an academic medical center, the Division of Endocrinology, Metabolism, and Molecular Medicine within the Department of Medicine at Northwestern University Feinberg School of Medicine (Feinberg) aims to improve the human health through scientific research.

About Clinical Trials
Clinical trials test or study drugs, surgical procedures, medical devices, or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

Division of Endocrinology, Metabolism, and Molecular Medicine - Department of Medicine
The following searchable list includes all the Division of Endocrinology, Metabolism, and Molecular Medicine - Department of Medicine clinical trials currently looking for participants.

Contact Us
Please feel free to contact us with inquiries about any of our ongoing research.

Trials
PHENOTYPING RARE GENETIC VARIANTS IN PCOS & MULTIETHNIC FINE-MAPPING OF POLYCYSTIC OVARY SYNDROME SUSCEPTIBILITY LOCI (P50 HD044405 / R01 HD085227)
Polycystic ovary syndrome (PCOS) is one of the most common disorders of reproductive age women worldwide and a leading risk factor for type 2 diabetes me…
Polycystic ovary syndrome (PCOS) is one of the most common disorders of reproductive age women worldwide and a leading risk factor for type 2 diabetes mellitus. We are mapping chromosomal regions that have a high likelihood of containing genes causing PCOS. These findings could also identify novel therapeutic targets and genetic variants conferring substantial risk that could be used for PCOS prediction and prevention.
We are currently recruiting 18-40 year old women with either PCOS (8 or fewer periods per year) or healthy control (regular monthly periods). Also, these women should not be using any type of hormonal birth control (pills, patches or injections).
Dunaif, Andrea EDunaif, Andrea E
  • Map it 303 E. Chicago Ave.
    Chicago, IL
STU00008096
More Info

For more information on this study please contact us:

Akinrotimi, Oludemilade 312 503 4385
Vitamin D and Type 2 Diabetes Study
Overweight adults, age 30 and above who are at risk for type 2 diabetes, are needed for a research study on a dietary supplement. During the study, participants will obtain information about their health, receive educational information on the prevention of diabete…
Overweight adults, age 30 and above who are at risk for type 2 diabetes, are needed for a research study on a dietary supplement. During the study, participants will obtain information about their health, receive educational information on the prevention of diabetes, and be required to take a dietary supplement daily. Participation in the study will last for up to 4 years. Participants will receive a stipend for completing all study visits. People diagnosed with diabetes, kidney stones, or kidney disease are not eligible. Other exclusions apply. For more information or to see if you qualify, please call 312-503-3413, email d2d@northwestern.edu or visit www.d2dstudy.org. (Sponsored by the National Institutes of Health)
-Adults 30 and older, BMI 24 and above, having pre-diabetes as determined by the following: fasting glucose: 100-125, HbA1c: 5.7-6.4
Neff, Lisa MNeff, Lisa M
STU00078718
More Info

For more information on this study please contact us:

Abou-El-Seoud, Dalya 312 503 7203
LCH_Measuring Human BAT Volume and Activity by Quantitative and Functional MRI (2014-15761)
In this study we will be comparing two different types of body scans and how they reveal fat tissues in the body. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) will be used to look fo…
In this study we will be comparing two different types of body scans and how they reveal fat tissues in the body. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) will be used to look for a specific type of metabolically active fat called brown fat (brown adipose tissue or BAT). Understanding more about BAT and how it relates to metabolism could eventually lead to the development of obesity treatments by encouraging weight loss. You may be eligible if you are male, normal weight or obese, healthy, nonsmoking and between the ages of 18-24. The study includes 3-4 separate visits to Northwestern Memorial Hospital and Lurie Children’s, laboratory testing and medical imaging study. Volunteers will receive compensation and reimbursement for participation. Call 312-503-3413 or email jennifer.lewandowski@northwestern.edu for more information.
You may be eligible if you are male, normal weight or obese, healthy, nonsmoking and between the ages of 18-24.
Deng, JieDeng, Jie
STU00099042
More Info

For more information on this study please contact us:

Abou-El-Seoud, Dalya 312 503 7203
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
The study aims to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It is a pivotal trial intended to support the registration of LCI699 for the treatment of patie…
The study aims to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It is a pivotal trial intended to support the registration of LCI699 for the treatment of patients with Cushing's disease in the EU, Japan, and other countries.
Molitch, Mark EMolitch, Mark E
NCT02180217 STU00100063
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 dia…
The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
• Subjects with type 2 diabetes mellitus
• Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on the following criteria: Persistent very high albuminuria defined as urinary albumin-to-creatinine ratio (ACR) of > 300 mg/g in 2 out of 3 first morning void samples and estimated glomerular filtration rate (eGFR) 25 - < 75 mL/min/1.73 m² Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), but not both, for at least 3 months
• Serum potassium
Molitch, Mark EMolitch, Mark E
NCT02540993 STU00201605
More Info

For more information on this study please contact us:

Adelman, Daphne T 312 908 9002
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated …
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref). The purpose of this study is to compare the efficacy safety and patient reported outcomes between oral octreotide capsules and injectable somatostatin analogs.
Molitch, Mark EMolitch, Mark E
NCT02685709 STU00202258
More Info

For more information on this study please contact us:

1-855-NU-STUDY